Dublin, 31 Dec. 2021 (GLOBE NEWSWIRE) — The “Chinese Temozolomide Market Investigation Report 2021-2025” report has been added to from ResearchAndMarkets.com offer.
The sales value of Temozolomide in the Chinese market increased year on year from 2016 to 2019. Due to the impact of COVID-19 on the entire diagnostic and treatment departments of Chinese hospitals, the value of sales of Temozolomide in the Chinese market decreased to CNY 793 million. in 2020 and the CAGR of temozolomide in sales value from 2016 to 2020 is 9.04%.
Temozolomide is a second generation alkylating agent. It is an oral chemotherapy drug used to treat brain cancers such as adult malignant glioma and malignant melanoma. It was developed by Merck & Co., Inc. The drug was approved to enter the Chinese market under the trade name TEMODAL in 2007. In 2020, temozolomide was included in class B medical insurance in China. There are many manufacturers in the Chinese market in 2020, among which Merck Sharp & Dohme Ltd is the main manufacturer.
The analyst expects that with the relief of COVID-19, the sales value of Temozolomide in the Chinese market will experience restorative growth from 2021 to 2025. Additionally, as the incidence of primary cancer of the brain increases, other cancers can cause secondary brain cancer. .
Therefore, with the widespread use of digital electronic products and the increase in the incidence of other cancers, the incidence of brain cancer is also increasing year by year, the sales value and sales volume of Temozolomide for the treatment of brain cancer will continue to rise.
At the same time, Temozolomide has the characteristics of easily penetrating the blood-cerebrospinal barrier and having mild adverse effects. The analyst predicts that the value and sales volume of Temozolomide in the Chinese market may increase from 2021 to 2025.
The impact of COVID-19 on the Chinese temozolomide market
China Temozolomide Sales Value 2016-2020
Competitive Landscape of Chinese Temozolomide Market
Temozolomide Price in China
Temozolomide Price in China by Regions and Manufacturers
Analysis of factors affecting the development of the Chinese temozolomide market
China Temozolomide Market Outlook from 2021 to 2025
Main topics covered:
1 Relevant Concepts of Temozolomide
1.1 Indications for temozolomide
1.2 Development of Temozolomide in China
1.3 Government Approval of Temozolomide in China
1.4 The impact of COVID-19 on Temozolomide sales in China
2 China Temozolomide Sales, 2016-2020
2.1 Temozolomide Sales Value
2.1.1 Overall sales value
2.1.2 Sales Value by Region
2.2 Temozolomide Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 China Temozolomide Sales by Dosage Form, 2016-2020
2.3.2 Analysis of other dosage forms
3 Analysis of Temozolomide Key Manufacturers in China in 2020
3.1 Key Manufacturers Market Share Analysis of Temozolomide
3.1.1 Market Share Survey by Sales Value
3.1.2 Market Share Survey by Sales Volume
3.2 Merck Sharp & Dohme Ltd.
3.2.1 Company profile
3.2.2 TEMODAL (Temozolomide by Merck Sharp & Dohme Ltd) Sales in China
3.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
3.3.1 Company Profile
3.3.2 China Diqing (Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Temozolomide) Sales
3.4 Beijing Shuanglu Pharmaceutical Co., Ltd.
3.4.1 Company Profile
3.4.2 China Jiaoning (Beijing Shuanglu Pharmaceutical Co., Ltd. Temozolomide) Sales
3.5 Schering-Plough Canada
3.5.1 Business Profile
3.5.2 TEMODAL (Schering-Plough Canada’s Temozolomide) Sales in China
3.6 Jiangsu Hengrui Medicine Company Ltd.
3.6.1 Company Profile
3.6.2 Jiangsu Hengrui Medicine Company Ltd. Temozolomide Sales in China
4 Temozolomide Price for Different Manufacturers in China, 2020-2021
4.1 Merck Sharp & Dohme Ltd (TEMODAL)
4.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (Diqing)
4.3 Beijing Shuanglu Pharmaceutical Co., Ltd. (Jiaoning)
4.4 Schering-Plough Canada (TEMODAL)
4.5 Jiangsu Hengrui Medicine Company Ltd.
5 China Temozolomide Drug Market Outlook, 2021- 2025
5.1 Influencing Factors of China Temozolomide Market Development
5.2 Market Size Forecast
5.3 Market Trend Forecast
Merck Sharp & Dohme Ltd (TEMODAL)
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (Diqing)
Beijing Shuanglu Pharmaceutical Co., Ltd. (Jiaoning)
Schering-Plough Canada (TEMODAL)
Jiangsu Hengrui Medicine Company Ltd.
For more information on this report, visit https://www.researchandmarkets.com/r/bit0v2
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900